Abstract
Nanomedicines have the potential to overcome some of the major drawbacks of conventional drugs, offering unique biomedical and biophysical properties that can enhance therapeutic performance indices. Despite the research advancements in the development of nanoparticles for a wide range of biomedical applications for the treatment and diagnosis of diseases, there exist significant limitations that obstruct the successful conversion of lab-scale technologies into commercial scales. In the case of diabetes, the emergence of nanomedicines has created new opportunities to develop personalized treatment modalities. However, the challenges associated with the commericialization of nanomedicines persist, transcending from large-scale production of nanomedicines, clinical evaluation and safety concerns, and market approval and sustainability as an alternative treatment strategy for diabetes. This chapter discusses some of the limitations of nanomedicines toward commercialization, emphasizing on limitations relating to diabetes, and some potential solutions. In addition, the future of nanomedicines in diagnosis and treatment applications of diabetes are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
